Pharmacological properties of novel TRPC channel inhibitors

Shigeki Kiyonaka, Kenta Kato, Motohiro Nishida, Yasuo Mori

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Ca2+ signals control diverse cellular processes, ranging from ubiquitous activities like gene expression to tissue specific responses such as lymphocyte activation and cardiac diseases. TRPC channels control Ca 2+ influxes that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a novel pyrazole compound (Pyr3) which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In B lymphocytes, Pyr3 eliminated the B cell receptor-induced Ca2+ oscillation regulated by TRPC3-mediated Ca2+ influx. In the cardiac system, Pyr3 attenuates activation of nuclear factor of activated T cells and hypertrophic growth in myocytes and pressure overload-induced hypertrophy in vivo. Thus, the TRPC3-selective inhibitor Pyr3 is useful for treatments of TRPC3-mediated diseases and for clarification of crucial and widespread functions of TRPC3 as well.

Original languageEnglish
Pages (from-to)303-311
Number of pages9
JournalYakugaku Zasshi
Volume130
Issue number3
DOIs
Publication statusPublished - Mar 1 2010

Fingerprint

B-Lymphocytes
Pharmacology
NFATC Transcription Factors
Type C Phospholipases
Lymphocyte Activation
Amides
Muscle Cells
Hypertrophy
Heart Diseases
Cell Membrane
Gene Expression
Pressure
Growth
Proteins
pyrazole
TRPC3 cation channel

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacological properties of novel TRPC channel inhibitors. / Kiyonaka, Shigeki; Kato, Kenta; Nishida, Motohiro; Mori, Yasuo.

In: Yakugaku Zasshi, Vol. 130, No. 3, 01.03.2010, p. 303-311.

Research output: Contribution to journalReview article

Kiyonaka, Shigeki ; Kato, Kenta ; Nishida, Motohiro ; Mori, Yasuo. / Pharmacological properties of novel TRPC channel inhibitors. In: Yakugaku Zasshi. 2010 ; Vol. 130, No. 3. pp. 303-311.
@article{72a5bb1a2b554310ac8de8fb5f579ccf,
title = "Pharmacological properties of novel TRPC channel inhibitors",
abstract = "Ca2+ signals control diverse cellular processes, ranging from ubiquitous activities like gene expression to tissue specific responses such as lymphocyte activation and cardiac diseases. TRPC channels control Ca 2+ influxes that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a novel pyrazole compound (Pyr3) which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In B lymphocytes, Pyr3 eliminated the B cell receptor-induced Ca2+ oscillation regulated by TRPC3-mediated Ca2+ influx. In the cardiac system, Pyr3 attenuates activation of nuclear factor of activated T cells and hypertrophic growth in myocytes and pressure overload-induced hypertrophy in vivo. Thus, the TRPC3-selective inhibitor Pyr3 is useful for treatments of TRPC3-mediated diseases and for clarification of crucial and widespread functions of TRPC3 as well.",
author = "Shigeki Kiyonaka and Kenta Kato and Motohiro Nishida and Yasuo Mori",
year = "2010",
month = "3",
day = "1",
doi = "10.1248/yakushi.130.303",
language = "English",
volume = "130",
pages = "303--311",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "公益社団法人 日本薬学会",
number = "3",

}

TY - JOUR

T1 - Pharmacological properties of novel TRPC channel inhibitors

AU - Kiyonaka, Shigeki

AU - Kato, Kenta

AU - Nishida, Motohiro

AU - Mori, Yasuo

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Ca2+ signals control diverse cellular processes, ranging from ubiquitous activities like gene expression to tissue specific responses such as lymphocyte activation and cardiac diseases. TRPC channels control Ca 2+ influxes that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a novel pyrazole compound (Pyr3) which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In B lymphocytes, Pyr3 eliminated the B cell receptor-induced Ca2+ oscillation regulated by TRPC3-mediated Ca2+ influx. In the cardiac system, Pyr3 attenuates activation of nuclear factor of activated T cells and hypertrophic growth in myocytes and pressure overload-induced hypertrophy in vivo. Thus, the TRPC3-selective inhibitor Pyr3 is useful for treatments of TRPC3-mediated diseases and for clarification of crucial and widespread functions of TRPC3 as well.

AB - Ca2+ signals control diverse cellular processes, ranging from ubiquitous activities like gene expression to tissue specific responses such as lymphocyte activation and cardiac diseases. TRPC channels control Ca 2+ influxes that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a novel pyrazole compound (Pyr3) which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In B lymphocytes, Pyr3 eliminated the B cell receptor-induced Ca2+ oscillation regulated by TRPC3-mediated Ca2+ influx. In the cardiac system, Pyr3 attenuates activation of nuclear factor of activated T cells and hypertrophic growth in myocytes and pressure overload-induced hypertrophy in vivo. Thus, the TRPC3-selective inhibitor Pyr3 is useful for treatments of TRPC3-mediated diseases and for clarification of crucial and widespread functions of TRPC3 as well.

UR - http://www.scopus.com/inward/record.url?scp=77649247811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649247811&partnerID=8YFLogxK

U2 - 10.1248/yakushi.130.303

DO - 10.1248/yakushi.130.303

M3 - Review article

C2 - 20190514

AN - SCOPUS:77649247811

VL - 130

SP - 303

EP - 311

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 3

ER -